13754-42-2

Basic information

• Product Name: 4-benzoylpiperazin-2-one
• CAS NO: 13754-42-2
• Molecular Formula: C₁₁H₁₂N₂O₂
• Molecular Weight: 204.2252
• Mol File: 13754-42-2.mol

Chemical Properties

• Boiling Point: 463.15°C at 760 mmHg
• Flash Point: 233.905°C
• Density: 1.222g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: 4-benzoylpiperazin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-benzoylpiperazin-2-one(13754-42-2)
• EPA Substance Registry System: 4-benzoylpiperazin-2-one(13754-42-2)

Safety Data

• Hazardous Substances Data: 13754-42-2(Hazardous Substances Data)

Upstream product

• 5625-67-2 2-Ketopiperazine 
• 65-85-0 benzoic acid 
• 98-88-4 benzoyl chloride 

Downstream Products

• 1016538-57-0 C₁₄H₁₆N₂O₃ 
• 1016538-58-1 C₁₃H₁₄N₂O₃ 
• 1416958-92-3 allyl 1,4-dibenzoyl-2-methyl-3-oxopiperazine-2-carboxylate 
• 103732-50-9 (3S,4R)-4-(4-Benzoyl-2-oxo-piperazin-1-yl)-3-hydroxy-2,2-dimethyl-chroman-6-carbonitrile 

Relevant articles and documents

1,4-disubstituted-2-piperazinone compounds and pharmaceutical use thereof

The invention belongs to the technical field of medicine and relates to a 1,4-disubstituted-2-piperazinone compound having a general structure formula of the formula I, and pharmaceutical use thereof.The compound can selectively inhibit activity of glycogen syntheses kinase 3beta (GSK 3beta), and can be used for preparing medicines preventing and/or treating diseases with GSK 3beta abnormal pathological features, the diseases including cancer, neurological disease, metabolic syndrome and the like.

Enantioselective synthesis of α-secondary and α-tertiary piperazin-2- Ones and piperazines by catalytic asymmetric allylic alkylation

The asymmetric palladium-catalyzed decarboxylative allylic alkylation of differentially N-protected piperazin-2- ones allows the synthesis of a variety of highly enantioenriched tertiary piperazine-2-ones. Deprotection and reduction affords the corresponding tertiary piperazines, which can be employed for the synthesis of medicinally important analogues. The introduction of these chiral tertiary piperazines resulted in imatinib analogues which exhibited comparable antiproliferative activity to that of their corresponding imatinib counterparts.

Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers

A series of 2-oxopiperazine, 4-aminomethyl-, 3-amino- and 3-aminomethylpiperidine analogues of DM235 (sunifiram) and MN19 (sapunifiram), two previously reported potent cognition-enhancers, have been synthesized and tested in the mouse passive-avoidance test. The compounds display minimal effective doses in the range 0.3-10 mg/kg. Although the new substances do not show improved activity when compared to the parent compounds, some useful information has been obtained to understand structure-activity relationships. In addition, the 3-aminopiperidine moiety appears to be a promising scaffold to synthesize new drugs endowed with cognition-enhancing activity.